AKBA Stock Recent News
AKBA LATEST HEADLINES
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m.
In the world of investment, penny stocks hold a unique position. Often priced at $5 per share or less, these are typically shares of small-cap companies that trade at relatively low prices.
Akebia Therapeutics Inc. is rated a Strong Buy due to its overly discounted revenue and strong prospects in the large Chronic Kidney Disease market. The company's valuation should be at least $716 million, more than 3x its current valuation, considering just Auryxia's revenue and the Healthcare Price/Revenue sector ratio. Risks include more total liabilities than total assets, cash flow negativity, stiff competition in the CKD drug market, and the possibility of FDA not approving vadadustat.
Akebia gained approval for Vafseo, its anemia therapy for chronic kidney disease patients, in Great Britain. The company is awaiting word on its appeal to the FDA to get approval for the therapy in the U.S. In May, Akebia said it has $57 million, enough cash to fund operations for another 12 months.
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2023 Earnings Conference Call May 8, 2023 8:30 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor and Corporate Communications John Butler - Chief Executive Officer Dave Spellman - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Thomas Yip - H.C. Wainwright Operator Good day, and thank you for standing by.
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
Analysts say these could be penny stocks to buy. Do you agree with their outlook?
Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.